

Melatonin role in skeletal muscle disorders

S. SALUCCI¹, S. TAURONE², S. BURATTINI¹, P. GOBBI¹, J. CLAUSI¹, M. BATTISTELLI¹

¹Department of Biomolecular Sciences, Carlo Bo Urbino University, Urbino, Italy

²Department of Sensory Organs, Sapienza University of Rome, Rome, Italy

Sara Salucci and Samanta Taurone equally contributed to the work

Abstract. – **OBJECTIVE:** This review discusses the impact of the neuro-hormone melatonin on skeletal muscle disorders based on recent literature data with the aim to clarify the utility of the melatonin therapy in patients affected by muscle diseases.

MATERIALS AND METHODS: It has been pointed out the possible role of melatonin as a food supplement to cure muscular disorders characterized by muscle wasting. Oxidative damage has been proposed as one of the major contributors of the skeletal muscle decline occurring both in physiological and pathological conditions. It is known that excessive oxidant levels lead to mitochondrial damage, and in turn, contribute to apoptotic signaling activation and autophagic impairment. This condition is common in a variety of skeletal muscle disorders.

RESULTS: The scientific evidence enhances the antioxidant effect of melatonin, that has been demonstrated by several studies both in vitro and in vivo. This effect counteracts mitochondrial impairments and reduces oxidative stress and autophagic alterations in muscle fibers. Its beneficial role in restoring muscle decline, takes place mainly in atrophic conditions correlated to muscle aging.

CONCLUSIONS: The findings of the research suggest that melatonin may be considered as a valid dietary supplement, useful to prevent muscle wasting, in particular, in sarcopenia-associated diseases.

Key Words:

Melatonin, Skeletal muscle, Muscle disorders.

Introduction

An analysis of the morpho-functional aspect of the skeletal muscle and of the melatonin molecule has been carried out, based on recent evidence derived from the literature. The objective was to better understand the possible role of the melatonin as preventive and curative agent of some skeletal

muscle disorders. Muscle dystrophy and atrophy conditions were therefore correlated with published data on the use of melatonin use in these pathologies.

Material and Methods

Skeletal Muscle

Skeletal muscular tissue, essential for voluntary movements and postural maintenance, plays a crucial role in controlling thermal regulation, nutritional balance, glucose uptake, and endocrine activity too¹⁻³. Therefore, loss of skeletal muscle mass has been associated with impaired whole body glucose homeostasis, falls, fractures, disability and chronic diseases⁴⁻⁶.

Skeletal muscle tissue (Figure 1) is characterized by a well-organized arrangement of multinucleated and post-mitotic muscle fibers and associated connective tissue. In addition, satellite cells can be found in skeletal muscle, located between the sarcolemma and the basal lamina, with the aim to contribute to muscle growth, repair, and regeneration⁷.

Skeletal muscle is a tissue formed by multiple types of fibers. Briefly, type I fibers are slow contracting and use an oxidative metabolism. Differently, type II fibers are fast contracting and mainly glycolytic. Muscle mass reduction, typical of sarcopenia and aging, is primarily due to a loss of muscle fibers particularly characterized by a preferential atrophy of type II fibers⁸. At the same time, a conversion of fast type II muscle fibers into slow type I fibers, with loss in muscle power and decline in protein synthesis (in particular for myosin heavy chains) has been described^{9,10}. Overall, these changes lead to a smaller, slower contracting muscle with resulting reduced capacity to adequately perform activities of daily living. These anatomical modifications have been, at

least partly, attributed to the age-related increase of oxidative stress damage. In fact, the skeletal muscle is the largest consumer of oxygen in the body with muscle fibers continuously generating ROS (especially during the contractile activity). Studies adopting muscle biopsies have confirmed that markers of oxidative stress are particularly and locally elevated in skeletal muscle of older adults and in patients affected by muscular dystrophies¹¹⁻¹⁶. On the other hand, the inadequacy of the antioxidant system, in particular catalase, glutathione transferase, and superoxide dismutase which appears downregulated in muscle atrophy, is not able to prevent damages^{17,18}.

This pro-oxidant status results in the alteration of mitochondrial DNA and abnormalities in the electron transport system, leading to reduced calcium uptake by the sarcoplasmic reticulum, irreversible damage of the cell, and its consequent death¹⁹⁻²¹. In the healthy muscle, proteins and aminoacids are ideally balanced between synthesis and breakdown. During immobilization and denervation, this equilibrium is disrupted with an increased breakdown rate of myofibrillar and mitochondrial proteins. As a consequence, mitochondria undergo a series of detrimental changes characterized by downregulation of PGC-1 α and

antioxidant defense, increased ROS generation, activated FoxO, NF κ B, and inflammation, enhanced ubiquitination, with mitophagy and finally apoptotic cascades²⁰⁻²⁶.

The progressive reduction of mitochondrial number and efficiency, represents a mechanism capable of inducing muscle atrophy and it seems involved in muscular dystrophy²⁷⁻³⁰. A relevant consequence of mitochondrial dysfunction is the activation of apoptosis, a mechanism believed to represent a final common pathway of several muscle disorders³¹. In particular, aberrantly enhanced apoptosis has been reported in muscle atrophy due to immobilization^{32,33} as well as both in muscles from patients with muscle dystrophy and in mouse models of muscle dystrophy^{34,35}.

In skeletal muscle biology, apoptosis has been described as a normal developmental event, both in proliferating myoblasts and in post-mitotic muscle fibers^{36,37}. Muscle atrophy conditions, which occur in neuromuscular diseases, muscle disuse, sarcopenia and aging, have been all associated to an increase of apoptosis which affected skeletal muscles mass.

Muscle wasting and weakness take places in physiological or pathological conditions, at least in part, due to an imbalance between apoptosis




Figure 1. Schematic illustration of a skeletal muscle fiber (A). It is possible to distinguish myonuclei (arrowheads) and satellite cells (arrows) localized beneath the surrounding basal lamina and outside the myofiber plasma membrane. These two cell types clearly appear in the longitudinal (B) and transversal (C) sections, obtained by means of transmission electron microscopy (TEM). In D, a confocal microscopy image shows transversal section of muscle in which the myofibers (in green, stained with talin, a structural protein of basal lamina) and myonuclei (in red, stained with propidium iodide) can be observed. Bars: 2 μ m (B, C); 10 μ m (D).




Figure 2. The figure describes melatonin possible action on muscle diseases. The images, obtained at transmission (TEM; A, B) and scanning (SEM; C, D) electron microscopy, show, the effect of the neurohormone in aged mouse skeletal muscle fibers and in a murine skeletal muscle cell line. TEM observations show a necrotic muscle fiber and altered mitochondria in aged mouse (A). This damage appears reduced after melatonin treatment (B). A thin C2C12 myotube (C) can be observed after treatment with a chemotherapeutic drug which causes loss of muscle mass. Melatonin treatment before drug is able to prevent muscle wasting (D)²⁸. Bars: 0.5 μm (A, B); 10 μm (C, D)

and autophagy³⁸. It should be noted that inhibition of autophagy and the consequent accumulation of dysfunctional organelles characterize several muscle disorders. Autophagy is an important mechanism for cell survival and for the clearance of damaged proteins and altered organelles³⁰. In particular, it exerts a critical role in myofiber integrity and muscle mass preservation. Its inhibition or alteration can contribute to myofiber degeneration and weakness in muscle diseases, characterized by accumulation of abnormal mitochondria and inclusions^{39,40}.

In this review, the effect of melatonin in preventing mitochondria dysfunctions leading to cell

death and autophagy impairment, which occur in skeletal muscle disorders, has been discussed.

Melatonin

Melatonin (N-acetyl-5-methoxytryptamine), the hormone produced by the pineal gland, has significantly broad actions including oncostatic effects^{41,42}, immune system stimulation^{43,44} and anti-inflammatory functions⁴⁵⁻⁴⁸.

Moreover, melatonin has been identified as a direct free radical scavenger⁴⁹ and an indirect antioxidant⁵⁰⁻⁵². Its function consists in the reduction of oxidative stress, i.e. molecular damage produced by reactive oxygen and nitrogen spe-

cies^{53,54}. So the ability of melatonin to scavenge free radicals is undoubtedly an important property in its protection against oxidative stress.

In addition, melatonin improves the intramitochondrial antioxidative defence by enhancing, for example, reduced glutathione levels. An additional action concerns in the inhibition of cardiolipin peroxidation and in maintaining the integrity of the mitochondrial membrane^{53,55}.

Some studies^{56,57} showed that melatonin anti-oxidant and anti-apoptotic effects may be explained by a direct interaction with the mitochondria transition pore. The recent discovery that mitochondria are a target for melatonin opened a new perspective to understand the mechanism of action of this neuro-hormone. In particular, it exerts a direct role in mitochondrial homeostasis^{28,58}, which may explain its protective effect in several disorders such as Parkinson's disease, Alzheimer's disease, epilepsy, aging, ischemia-reperfusion and sepsis and, recently, also in muscular diseases^{3,59}.

The exact structure of mitochondrial transition pore is not clearly established; however, it has been proposed to consist of a large complex located at the contact sites between mitochondrial inner and outer membranes. This complex controls the voltage-dependent anion channel, the adenine nucleotide translocator and some other proteins⁶⁰.

Opening of the permeability transition pore, a phenomenon described as mitochondrial permeability transition, causes a sudden increase in the permeability of the inner mitochondrial membrane. This event leads to dissipation of the mitochondrial potential, uncoupling of mitochondria pumps, swelling of the mitochondrial matrix and rupture of the outer mitochondrial membrane⁶¹. As a consequence, the release of pro-apoptotic factors (i.e., cytochrome c) from the intermembrane space to the cytoplasm, induces activation of caspase cascade responsible for apoptosis.

In the following sections the role of melatonin vs muscle disorders has been discussed. In particular, the action of melatonin on dystrophies as well as in muscle atrophy following aging or sarcopenia has been described.

Results

Melatonin Effect on Muscle Dystrophy

Progressive muscle weakness is a typical feature of dystrophic patients^{3,62}. Duchenne muscular dystrophy (DMD) and Becker muscular dystro-

phy (BMD) are muscular wasting disorders that affect both skeletal and cardiac muscle as result of mutations in the dystrophin gene⁶³. A progressive muscle degeneration affects dystrophic patients which lose ambulation. If the disease is untreated, patients die from cardiac or respiratory insufficiency at the average age of 19⁶⁴.

Even if DMD and BMD are genetic diseases, they are characterized by muscular frailty of the elderly, abnormal calcium homeostasis, mitochondria dysfunctions and strong oxidative damage. All these conditions contribute to the onset of the muscle degeneration.

Dystrophic muscle fibers showed some typical alterations such as, the presence of necrotic events followed by regeneration, release of pro-inflammatory cytokines and oxidative stress mechanism activation^{65,66}. Therefore, inflammation and oxidative stress represent the pathogenic pathways targeted by nutraceutical therapies in dystrophy pathology.

In particular, the sources of oxidative stress in DMD are related to inflammatory cells, NAD(P)H oxidase, altered mitochondrial function or to ROS producing enzymes. Given that dystrophic disease is exacerbated, at least in part, by oxidative stress, melatonin could have some therapeutic benefit. First of all, thanks to its lipophilicity, it can easily pass-through cell membranes and the blood-brain barrier, becoming an effective antioxidant. In skeletal muscle, melatonin preserves mitochondrial function^{28,52} and regulates calcium homeostasis during muscle contraction^{67,68}. Some studies highlight the role of melatonin in preventing muscle wasting in dystrophic patients. In 2010, Chahbouni et al⁶⁹ demonstrated a significant increase of lipid peroxidation, nitrites and cytokine levels in plasma of DMD patients compared with controls. These plasma values appeared down-regulate in DMD patients treated with melatonin, suggesting that melatonin administration significantly reduced the hyperoxidative and inflammatory process in DMD subjects, by slowing down the muscle degenerative process⁶⁹.

Then, in 2011, Hibaoui et al⁷⁰ described melatonin action in a DMD mouse model in which the therapy with the neuro-hormone decreased plasma creatine kinase activity, a fundamental pattern involved in muscle injury. In addition, in DMD mouse, melatonin increased total glutathione content and lowered the oxidized/reduced glutathione ratio. These data enhanced melatonin ability in restoring the redox status in dystrophic muscle.

Despite some studies showed a benefit of melatonin

tonin in DMD pathologies, no recent data describe its role as therapeutic agent to cure these diseases.

On the other hand, previously we discussed the autophagy impairment, a harmful condition which leads to muscle damage and which is strictly correlated to the pathogenesis of muscle dystrophy⁷¹. It is known that excessive stimulation of autophagy in a normal muscle is detrimental because it causes depletion of proteins and organelles that are functional and necessary. This despite the fact that an adequate rate of autophagy is essential for the correct homeostasis of skeletal muscles^{30,72}.

Pharmacological treatments, with the capabilities of recovery both autophagy/mitophagy and mitochondrial function, represent an intriguing tool to reactivate autophagy in dystrophic muscles.

However, the role of melatonin in rescuing autophagy impairment in DMD phenotypes has been not described.

Melatonin Effect on Muscle Atrophy Conditions (Aging, Sarcopenia)

During healthy aging there is a progressive loss of muscle mass and consequently of skeletal muscle contractile strength that causes a decline in muscle function with a consequent important effect on the quality of life⁷³. This phenomenon has been widely observed during mammalian aging and can lead to increased morbidity and mortality. In this regard, about 40% of the human muscle is wasted from 20 to 80 years of age, associated with muscle strength decline.

There are likely several factors that contribute to muscle loss in aging. These include but may not be limited to: reduced protein synthesis^{74,75}, declines in neural function⁷⁶⁻⁷⁸, hormonal deficits⁷⁹, chronic inflammation⁸⁰⁻⁸², oxidative stress⁸³⁻⁸⁷, loss of mitochondrial function^{40,86-89}, inappropriate signaling in muscle, due at least in part, to inadequate nutrition⁹⁰⁻⁹³, nuclear apoptosis⁹⁴⁻¹⁰⁰, and reduced satellite cell function^{22,101,102}.

Sarcopenia is a multidimensional phenomenon of aging and represents a powerful risk factor for the development of negative health related events in the elderly. In fact, the relationships of sarcopenia with impaired physical performance, frailty, loss of functional independence, and increased risk of falls are all well established in the literature¹⁰³⁻¹⁰⁵.

The etiology of the sarcopenia is still unclear, but several mechanisms depending on muscle atrophy and fiber loss have been proposed¹⁰⁶. The main cause of these muscle changes is the accu-

mulation of genetic damages and mutations in aged mitochondrial DNA¹⁰⁷.

Although the etiology of sarcopenia is not clearly defined, numerous mechanisms involved in this phenomenon have been suggested. These events include denervation of the skeletal muscle fiber, increased levels of nuclear apoptosis and oxidative stress, alteration of the hormonal environment and increased inflammation¹⁰⁸⁻¹¹⁰.

Several papers described melatonin beneficial action in attenuating, reducing or preventing muscle damage during sarcopenia. Sayen et al¹¹¹, demonstrated that melatonin administration was able to prevent age-dependent mitochondrial changes in aged mice. Later¹¹², it has been demonstrated that melatonin administration had the ability to maintain muscle fiber numbers as well as muscle mass and activity in older animals⁵. In fact, melatonin reduced the percentage of interstitial spaces and the infiltration of collagen tissue, as well as the percentage of apoptotic nuclei in elderly muscles, reflecting the anti-inflammatory and antioxidant properties of melatonin. In addition, in sarcopenic subjects, melatonin is also able to maintain the normal architecture of mitochondria and to restore a normal autophagy process, thus avoiding age-mediated damage to muscle fibers, mitochondrial changes and apoptosis. These results confirmed the protective effect of melatonin on the prevention of mitochondrial impairment, on the reduction of oxidative stress, on autophagic alterations and on low chronic inflammation, which may explain the reduction of sarcopenic changes in patients⁶.

Since aging is characterized by an increase in oxidative stress that occurs during the development of sarcopenia, melatonin represents a valid candidate able to counteract free radical species increase.

Melatonin ability to improve the muscle function by reducing oxidative stress and inflammation in aged muscle has been summarized as follow:

- Melatonin and its metabolites serve as powerful antioxidants that protect the electron transport chain and mitochondrial DNA from oxidative damage more efficiently than other conventional antioxidants. This respiratory chain protection allows melatonin to increase ATP production in the mitochondria and thus to limit mitochondrial dysfunctions which affect sarcopenic muscles^{113,114}.
- It has been demonstrated that melatonin could induce or reduce autophagy. In relation to muscle, melatonin is a highly versatile

molecule and induces autophagy or inhibits it, depending on the pathological processes involved, since oxidative stress has a close relationship with autophagy⁷.

- Melatonin can reduce endoplasmic reticulum stress in skeletal muscle by increasing the expression of different proteins as well as mRNA levels. This process improves protein synthesis. Furthermore, melatonin is an important regulator of the proteasome and of lysosomal mechanisms, thus improving the quality of cellular activity.
- Melatonin also increases satellite cells following muscle injury in rats⁸ by reducing apoptotic processes, by modulating signalling pathways which causes significant muscle regeneration in these animals. Melatonin has a different antiapoptotic role in different cell lines. In normal skeletal muscle, melatonin prevents apoptosis and limits oxidative stress that causes the permeability of mitochondria to transition and subsequent death⁸. Melatonin significantly reduces or counteracts the various physiopathological processes specifically associated with sarcopenia^{10,11}.

Conclusions

Through the careful analysis of the literature, supported by previous experimental evidence of our group, we can conclude that melatonin, an ancient molecule produced by the pineal gland, could be used as a food supplement to cure muscular disorders characterized by muscle wasting. The scientific evidence enhances that melatonin counteracts mitochondrial impairments, reduces oxidative stress and autophagic alterations in muscle fibers (Figure 2). Its beneficial effect in restoring muscle decline takes place mainly in atrophic conditions correlated to muscle aging. Therefore, these findings suggest that melatonin may be considered as a safe dietary supplement useful to prevent or treat muscle wasting, in particular, in sarcopenia-associated diseases.

References

- 1) Meynial-Denis D, Guérin O, Schneider SM, Volkert D, Sieber CC. New strategies to fight against sarcopenia at old age. *J Aging Res* 2012; 2012: 676042.
- 2) Gouspillou G, Godin R, Piquereau J, Picard M, Mofarrahi M, Mathew J, Purves-Smith FM, Sgarbioto N, Hepple RT, Burelle Y, Hussain SNA. Protective role of Parkin in skeletal muscle contractile and mitochondrial function. *J Physiol* 2018; 596: 2565-2579.
- 3) Stacchiotti A, Favero G, Rodella LF. Impact of melatonin on skeletal muscle and exercise. *Cells* 2020; 9: 288.
- 4) Yang J. Enhanced skeletal muscle for effective glucose homeostasis. *Prog Mol Biol Transl Sci* 2014; 121: 133-163.
- 5) Ebner N, Sliziuk V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. *ESC Heart Failure* 2015; 2: 58-68.
- 6) Balogun S, Winzenberg T, Wills K, Scott D, Jones G, Aitken D, Callisaya ML. Prospective associations of low muscle mass and function with 10-year falls risk, incident fracture and mortality in community-dwelling older adults. *J Nutr Health Aging* 2017; 21: 843-848.
- 7) Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. *Calcif Tissue Int* 2015; 96: 183-195.
- 8) Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. *Physiol Rev* 2011; 91:1447-1531.
- 9) Wang Y and Pessin, JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. *Curr Opin Clin Nutr Metab Care* 2013; 16: 243-250.
- 10) Talbot J and Maves L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease. *Wiley Interdiscip Rev Dev Biol* 2016; 5: 518-534.
- 11) Lim PS, Cheng YM, Wei YH. Increase in oxidative damage to lipids and proteins in skeletal muscle of uremic patients. *Free Radic Res* 2002; 36: 295-301.
- 12) Gianni P, Jan KJ, Douglas MJ, Stuart PM, Tarnopolsky MA. Oxidative stress and the mitochondrial theory of aging in human skeletal muscle. *Exp Gerontol* 2004; 39: 1391-1400.
- 13) Choi MH, Ow JR, Yang N, Taneja R. Oxidative stress-mediated skeletal muscle degeneration: molecules, mechanisms, and therapies. *Oxid Med Cell Longev* 2016; Article ID 6842568.
- 14) Gomes MJ, Martinez PF, Pagan LU, Damatto RL, Cezar MDM, Lima ARR, Okoshi K, Okoshi MP. Skeletal muscle aging: influence of oxidative stress and physical exercise. *Oncotarget* 2017;8: 20428-20440.
- 15) Petrillo S, Pelosi L, Piemonte F, Travaglini L, Forcina L, Catteruccia M, Petrini S, Verardo M, D'Amico A, Musarò A, Bertini E. Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway. *Hum Mol Genet* 2017; 26: 2781-2790.
- 16) Serra AJ, Prokić MD, Vasconsuelo A, Pinto JR. Oxidative stress in muscle diseases: current and future therapy. *Oxid Med Cell Longev* 2018; 2018: 6439138.
- 17) Palomero J and Jackson MJ. Redox regulation in skeletal muscle during contractile activity and aging. *J o Animal Sci* 2010; 88: 1307-1313.
- 18) Kozakowska M, Pietraszek-Gremplewicz K, Jozkowicz A, Dulak J. The role of oxidative stress in

- skeletal muscle injury and regeneration: focus on antioxidant enzymes. *J Muscle Res Cell Motil* 2015; 36: 377-393.
- 19) Reid MB, Li YP. Cytokines and oxidative signaling in skeletal muscle. *Acta Physiol Scand* 2001; 171: 225-232.
 - 20) Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. *Biochim Biophys Acta* 2010; 1802: 396-405.
 - 21) Li H, Chen Q, Li C, Zhong R, Zhao Y, Zhang Q, Tong W, Zhu D, Zhang Y. Muscle-secreted granulocyte colony-stimulating factor functions as metabolic niche factor ameliorating loss of muscle stem cells in aged mice. *EMBO J* 2019; 38: e102154.
 - 22) Livnat-Levanon N, Glickman MH. Ubiquitin-proteasome system and mitochondria – reciprocity. *Biochim Biophys Acta* 2011; 1809: 80-87.
 - 23) Barberi L, Scicchitano BM, De Rossi M, Bigot A, Duguez S, Wielgosik A, Stewart C, McPhee J, Conte M, Narici M, Franceschi C, Mouly V, Butler-Browne G, Musaro A. Age-dependent alteration in muscle regeneration: the critical role of tissue niche. *Biogerontology* 2013; 14: 273-292.
 - 24) Marzetti E, Csiszar A, Dutta D, Balagopal G, Calvani R, Leeuwenburgh C. Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. *Am J Physiol Heart Circ Physiol* 2013; 305: H459-H476.
 - 25) Sullivan-Gunn MJ, Lewandowski PA. Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. *BMC Geriatr* 2013; 13: 104.
 - 26) Kang C, Yeo D, Ji LL. Muscle immobilization activates mitophagy and disrupts mitochondrial dynamics in mice. *Acta Physiol (Oxf)* 2016; 218: 188-197.
 - 27) Derbré F, Assi M, Lefevre-Orfila L, Vincent S, Chevalier M, Gueritat J, Salaun E, Rebillard A. Antioxidants and muscle atrophy in colon cancer: beneficial or deleterious effects? *Free Radic Biol Med* 2014; 75 Suppl 1: S22.
 - 28) Salucci S, Battistelli M, Baldassarri V, Burini D, Falcieri E, Burattini S. Melatonin prevents mitochondrial dysfunctions and death in differentiated skeletal muscle cells. *Microsc Res Tech* 2017; 80: 1174-1181.
 - 29) Pauly M, Angebault-Prouteau C, Dridi H, Nartarnicola C, Scheuermann V, Lacampagne A, Matecki S, Fauconnier J. ER stress disturbs SR/ER-mitochondria Ca²⁺ transfer: Implications in Duchenne muscular dystrophy. *Biochim Biophys Acta Mol Basis Dis* 2017; 1863: 2229-2239.
 - 30) Giordano FM, Burattini S, Buontempo F, Canonico B, Martelli AM, Papa S, Sampaolesi M, Falcieri E, Salucci S. Diet modulation restores autophagic flux in damaged skeletal muscle cells. *J Nutr Health Aging* 2019; 23: 739-745.
 - 31) Marzetti E, Leeuwenburgh C. Skeletal muscle apoptosis, sarcopenia and frailty at old age. *Exp Gerontol* 2006; 41: 1234-1238.
 - 32) Marzetti E, Hwang JCY, Lees HA, Wohlgemuth SE, Dupont-Versteegden EE, Carter CS, Bernabei R, Leeuwenburgh C. Mitochondrial death effectors: relevance to sarcopenia and disuse muscle atrophy. *Biochim Biophys Acta* 2010; 1800: 235-244.
 - 33) Roos S, Fyhr IM, Sunnerhagen KS, Moslemi AR, Oldfors A, Ullman M. Histopathological changes in skeletal muscle associated with chronic ischaemia. *APMIS* 2016; 124: 935-941.
 - 34) Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan GM, Bernardi P, Bonaldo P. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. *Nat Genet* 2003; 35: 367-371.
 - 35) Li Y, Yang Z, Wang Y, Cao X, Xu X. A neural network approach to analyze cross-sections of muscle fibers in pathological images. *Comput Biol Med* 2019; 104: 97-104.
 - 36) Salucci S, Burattini S, Baldassarri V, Battistelli M, Canonico B, Valmori A, Papa S, Falcieri E. The peculiar apoptotic behavior of skeletal muscle cells. *Histol Histopathol* 2013; 28: 1073-1087.
 - 37) Battistelli M, Salucci S, Guescini M, Curzi D, Stocchi V, Falcieri E. Skeletal muscle cell behavior after physical agent treatments. *Curr Pharm Des* 2015; 21: 3665-3672.
 - 38) Li Y, Jiang J, Liu W, Wang H, Zhao L, Liu S, Li P, Zhang S, Sun C, Wu Y, Yu S, Li X, Zhang H, Qian H, Zhang D, Guo F, Zhai Q, Ding Q, Wang L, Ying H. MicroRNA-378 promotes autophagy and inhibits apoptosis in skeletal muscle. *PNAS* 2018; 115: E10849-E10858.
 - 39) Marzetti E, Lees HA, Wohlgemuth SE, Leeuwenburgh C. Sarcopenia of aging: underlying cellular mechanisms and protection by calorie restriction. *BioFactors* 2009; 35: 28-35.
 - 40) Calvani R, Joseph AM, Adhietty PJ, Miccheli A, Bossola M, Leeuwenburgh C, Bernabei R, Marzetti E. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. *Biol Chem* 2013; 394: 393-414.
 - 41) Bejarano I, Redondo PC, Espino J, Rosado JA, Paredes S, Barriga C, Reiter RJ, Pariente JA, Rodríguez AB. Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells. *J Pineal Res* 2009; 46: 392-400.
 - 42) Salucci S, Burattini S, Battistelli M, Baldassarri V, Curzi D, Valmori A, Falcieri E. Melatonin prevents chemical-induced haemopoietic cell death. *Int J Mol Sci* 2014; 15: 6625-6640.
 - 43) Guerrero JM, Reiter RJ. Melatonin-immune system relationships. *Curr Top Med Chem* 2002; 2: 167-179.
 - 44) Hardeland R. Aging, melatonin, and the pro- and anti-inflammatory networks. *Int J Mol Sci* 2019; 20: 1223.
 - 45) Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. *Biochem Pharmacol* 2010; 80: 1844-1852.
 - 46) Paradies G, Paradies V, Ruggiero F, Petrosillo G. Protective role of melatonin in mitochondrial dysfunction and related disorders. *Arch. Toxicol* 2015; 89: 923-939.
 - 47) Chang CC, Huang TY, Chen HY, Huang TC, Lin LC, Chang YJ, Hsia SM. Protective effect of melatonin against oxidative stress-induced apoptosis and enhanced autophagy in human retinal

- pigment epithelium cells. *Oxid Med Cell Longev* 2018; 2018:9015765.
- 48) Gunata M, Parlakpinar H, Acet HA. Melatonin: a review of its potential functions and effects on neurological diseases. *Rev Neurol (Paris)* 2020; 176: 148-165.
 - 49) Korkmaz A, Topal T, Tan DX, Reiter RJ. Role of melatonin in metabolic regulation. *Rev Endocr Metab Disord* 2009; 10: 261-270.
 - 50) Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. *J Pineal Res* 2004; 36: 1-9.
 - 51) Salucci S, Burattini S, Battistelli M, Buontempo F, Canonico B, Martelli AM, Papa S, Falcieri E. Tyrosol prevents apoptosis in irradiated keratinocytes. *J Dermatol Sci* 2015; 80: 61-68.
 - 52) Salucci S, Baldassarri V, Canonico B, Burattini S, Battistelli M, Guescini M, Papa S, Stocchi V, Falcieri E. Melatonin behavior in restoring chemical damaged C2C12 myoblasts. *Microsc Res Tech* 2016; 79: 532-540.
 - 53) Reiter RJ, Tan DX, Manchester LC, El-Sawi MR. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. *Ann N Y Acad Sci* 2002; 959:2 38-250.
 - 54) Salucci S, Burattini S, Buontempo F, Martelli AM, Falcieri E, Battistelli M. Protective effect of different antioxidant agents in UVB-irradiated keratinocytes. *Eur J Histochem* 2017; 61: 2784.
 - 55) Hardeland R. Melatonin and the pathologies of weakened or dysregulated circadian oscillators. *J Pineal Res*. 2017; 62: e12377.
 - 56) Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TFW. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. *FASEB J* 2004; 18: 869-871.
 - 57) Supinski GS, Schroder EA, Callahan LA. Mitochondria and critical illness. *Chest* 2020; 157: 310-322.
 - 58) Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. *Int J Biochem Cell Biol* 2002; 34: 348-357.
 - 59) Hibaoui Y, Roulet E, Rugg UT. Melatonin prevents oxidative stress-mediated mitochondrial permeability transition and death in skeletal muscle cells. *J Pineal Res* 2009; 47: 238-252.
 - 60) Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. *Apoptosis* 2007; 12: 815-833.
 - 61) Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. *Annu Rev Pharmacol Toxicol* 2007; 47: 143-183.
 - 62) Salucci S, Falcieri E. Polyphenols and their potential role in preventing skeletal muscle atrophy. *Nutr Res* 2020; 74: 10-22.
 - 63) Le Rumeur E. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. *Bosn J Basic Med Sci* 2015; 15: 14-20.
 - 64) Woodman KG, Coles CA, Lamandé SR, White JD. Nutraceuticals and their potential to treat duchenne muscular dystrophy: separating the credible from the conjecture. *Nutrients* 2016; 8: 713.
 - 65) Tidball JG, Wehling-Henricksa M. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. *Mol Gene Metab* 2004; 82: 312-320.
 - 66) Tidball JG, Wehling-Henricksa M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. *J Physiol* 2007; 578: 327-336.
 - 67) Yeung HM, Hung MW, Fung ML. Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. *J Pineal Res* 2008; 45: 373-382.
 - 68) Gomez-Pinilla PJ, Camello PJ, Pozo MJ. Protective effect of melatonin on Ca²⁺ homeostasis and contractility in acute cholecystitis. *J Pineal Res* 2008; 44: 250-260.
 - 69) Chahbouni Mariam, Escames G, Venegas C, Sevilla B, García JA, López LC, Muñoz-Hoyos A, Molina-Carballo A, Acuña-Castroviejo D. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. *J Pineal Res* 2010; 48: 282-289.
 - 70) Hibaoui Y, Reutenauer-Patte J, Patthey-Vuadens OT, Rugg UM, Dorchie O. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy. *J Pineal Res* 2011; 51: 163-171.
 - 71) Grumati P, Coletto L, Sandri M, Bonaldo P. Autophagy induction rescues muscular dystrophy. *Autophagy* 2011; 7: 426-428.
 - 72) Valladares D, Utreras-Mendoza Y, Campos C, Morales C, Diaz-Vegas A, Contreras-Ferrat A, Westermeier F, Jaimovich E, Marchi S, Pinton P, Lavandero S. IP(3) receptor blockade restores autophagy and mitochondrial function in skeletal muscle fibers of dystrophic mice. *Biochim Biophys Acta Mol Basis Dis* 2018; 1864: 3685-3695.
 - 73) Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al.; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; 39: 412-423.
 - 74) Dickinson JM, Volpi E, Rasmussen BB. Exercise and nutrition to target protein synthesis impairments in aging skeletal muscle. *Exerc Sport Sci Rev* 2013; 41: 216-223.
 - 75) Churchward-Venne TA, Breen L, Phillips SM. Alterations in human muscle protein metabolism with aging: Protein and exercise as countermeasures to offset sarcopenia. *BioFactors* 2014; 40: 1-7.
 - 76) Drey M, Grosch C, Neuwirth C, Bauer JM, Sieber CC. The motor unit number index (MUNIX) in sarcopenic patients. *Exp Gerontol* 2013; 48: 381-384.
 - 77) Kwan P. Sarcopenia: the gliogenic perspective. *Mech Ageing Dev*. 2013; 134: 349-355.
 - 78) Mosole S, Carraro U, Kern H, Loeffler S, Fruhmann H, Vogelaer M, Burggraf S, Mayr W, Krenn M, Pater-

- nostro-Sluga T, Hamar D, Cvecka J, Sedliak M, Tirpakova V, Sarabon N, Musarò A, Sandri M, Protasi F, Nori A, Pond A, Zampieri S. Long-term high-level exercise promotes muscle reinnervation with age. *J Neuropathol Exp Neurol* 2014; 73: 284-294.
- 79) Michalakis K, Goulis DG, Vazaiou A, Mintzioti G, Polymeris A, Abrahamian-Michalakis A. Obesity in the ageing man. *Metab Clin Exp* 2013; 62: 1341-1349.
- 80) Lee CE, McArdle A, Griffiths RD. The role of hormones, cytokines and heat shock proteins during age-related muscle loss. *Clin Nutr* 2007; 26: 524-534.
- 81) Degens H. The role of systemic inflammation in age-related muscle weakness and wasting. *Scand J Med Sci Sports* 2010; 20: 28-38.
- 82) Mavros Y, Kay S, Simpson KA, Baker MK, Wang Y, Zhao RR, Meiklejohn J, Climstein M, O'Sullivan AJ, de Vos N, Baune BT, Blair SN, Simar D, Rooney K, Singh NA, Fiatarone Singh MA. Reductions in C-reactive protein in older adults with type 2 diabetes are related to improvements in body composition following a randomized controlled trial of resistance training. *J Cachexia Sarcopenia Muscle* 2014; 5: 111-120.
- 83) Hiona A, Leeuwenburgh C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. *Exp Gerontol* 2008; 43: 24-33.
- 84) Jackson JR, Ryan MJ, Hao Y, Alway SE. Mediation of endogenous antioxidant enzymes and apoptotic signaling by resveratrol following muscle disuse in the gastrocnemius muscles of young and old rats. *Am J Physiol Regul Integr Comp Physiol* 2010; 299: R1572-R158110.
- 85) Armand AS, Laziz I, Djeghloul D, Lecolle S, Bertrand AT, Biondi O, De Windt LJ, Chanoine C. Apoptosis-inducing factor regulates skeletal muscle progenitor cell number and muscle phenotype. *PLoS One* 2011; 6: e27283.
- 86) Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, Leeuwenburgh C. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. *Int J Biochem Cell Biol* 2013; 45: 2288-2301.
- 87) Sullivan-Gunn MJ, Lewandowski PA. Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. *BMC Geriatr* 2013; 13:104.
- 88) Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. *Aging Cell* 2008; 7: 2-12.
- 89) Ljubicic V, Joseph AM, Adihetty PJ, Huang JH, Saleem A, Uguccioni G, Hood DA. Molecular basis for an attenuated mitochondrial adaptive plasticity in aged skeletal muscle. *Aging (Albany NY)* 2009; 1: 818-830.
- 90) Burgos PR. Therapeutic approach to malnutrition and sarcopenia. *Nestle Nutr Inst Workshop* Sept 2012; 72: 85-99.
- 91) Ghosh S, Lertwattanak R, Garduno JD, Galeana JJ, Li J, Zamarripa F, Lancaster JL, Mohan S, Hussey S, Musi N. Elevated muscle TLR4 expression and metabolic endotoxemia in human aging. *J Gerontol A Biol Sci Med Sci* 2015; 70: 232-246.
- 92) Welch AA. Nutritional influences on age-related skeletal muscle loss. *Proc Nutr Soc* 2014; 73: 16-33.
- 93) Welch AA, MacGregor AJ, Minihane AM, Skinner J, Valdes AA, Spector TD, Cassidy A. Dietary fat and fatty acid profile are associated with indices of skeletal muscle mass in women aged 18-79 years. *J Nutr* 2014; 144: 327-334.
- 94) Sjostrom M, Lexell J, Downham DY. Differences in fiber number and fiber type proportion within fascicles. A quantitative morphological study of whole vastus lateralis muscle from childhood to old age. *Anat Rec* 1992; 234: 183-189.
- 95) Alway SE, Degens H, Lowe DA, Krishnamurthy G. Increased myogenic repressor Id mRNA and protein levels in hindlimb muscles of aged rats. *Am J Physiol Regul Integr Comp Physiol* 2002; 282: R411-R422.
- 96) Alway SE, Morissette MR, Siu PM. "Aging and apoptosis in muscle" in *Handbook of the Biology of Aging*, eds Masoro EJ, Austad S. (Amsterdam: Elsevier), 2011; 64-139.
- 97) Leeuwenburgh C. Role of apoptosis in sarcopenia. *J Gerontol A Biol Sci Med Sci* 2003; 58: 999-1001.
- 98) Dupont-Versteegden EE. Apoptosis in muscle atrophy: relevance to sarcopenia. *Exp Gerontol* 2005; 40: 473-481.
- 99) Alway SE, Siu PM. Nuclear apoptosis contributes to sarcopenia. *Exerc Sport Sci Rev* 2008; 36: 51-57.
- 100) Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. *Aging Cell* 2008; 7: 2-12.
- 101) Conboy IM, Rando TA. Aging, stem cells and tissue regeneration: lessons from muscle. *Cell Cycle* 2005; 4: 407-410.
- 102) Sniijders T, Verdijk LB, van Loon LJ. The impact of sarcopenia and exercise training on skeletal muscle satellite cells. *Ageing Res Rev* 2009; 8: 328-338.
- 103) Sieber CC. Malnutrition and sarcopenia. *Aging Clin Exp Res* 2019; 31: 793-798.
- 104) Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *Lancet* 2019; 393: 2636-2646.
- 105) Woo J. Sarcopenia. *Clin Geriatr Med* 2017; 33: 305-314.
- 106) Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. *Osteoporos Int* 2010; 21: 543-559.
- 107) Huang DD, Fan SD, Chen XY, Yan XL, Zhang XZ, Ma BW, Yu DY, Xiao WY, Zhuang CL, Yu Z. Nrf2 deficiency exacerbates frailty and sarcopenia by impairing skeletal muscle mitochondrial biogenesis and dynamics in an age-dependent manner. *Exp Gerontol* 2019; 119: 61-73.
- 108) Barns M, Gondro C, Tellam RL, Radley-Crabb HG, Grounds MD, Shavlakadze T. Molecular analyses provide insight into mechanisms underlying sarcopenia and myofibre denervation in old skeletal muscles of mice. *Int J Biochem Cell Biol* 2014; 53: 174-185.
- 109) Tower J. Programmed cell death in aging. *Ageing Res Rev* 2015; 23: 90-100.

- 110) Abrigo J, Marín T, Aguirre F, Tacchi F, Vilos C, Simon F, Arrese M, Cabrera D, Cabello-Verrugio C. N-Acetyl Cysteine Attenuates the Sarcopenia and Muscle Apoptosis Induced by Chronic Liver Disease. *Curr Mol Med* 2019; 20: 60-71.
- 111) Sayed RKA, Fernández-Ortiz M, Diaz-Casado ME, Rusanova I, Rahim I, Escames G, López LC, Mokhtar DM, Acuña-Castroviejo D. The protective effect of melatonin against age-associated, sarcopenia-dependent tubular aggregate formation, lactate depletion, and mitochondrial changes. *J Gerontol A Biol Sci Med Sci* 2018; 73: 1330-1338.
- 112) Sayed RKA, Fernández-Ortiz M, Diaz-Casado ME, Aranda-Martínez P, Fernández-Martínez J, Guerra-Librero A, Escames G, López LC, Alsaad-awy RM, Acuña-Castroviejo D. Lack of NLRP3 inflammasome activation reduces age-dependent sarcopenia and mitochondrial dysfunction, favoring the prophylactic effect of melatonin. *J Gerontol A Biol Sci Med Sci* 2019; 74: 1699-1708.
- 113) Coto-Montes A, Boga JA, Tan DX, Reiter RJ. Melatonin as a potential agent in the treatment of Sarcopenia. *Int J Mol Sci* 2016; 17: 1771.
- 114) Stratos I, Richter N, Rotter R, Li Z, Zechner D, Mittlmeier T, Vollmar B. Melatonin restores muscle regeneration and enhances muscle function after crush injury in rats. *J Pineal Res* 2012; 52: 62-70.